Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

A. Trojani, E. Pungolino, G. Rossi, M. D'Adda, M. Lodola, B. D. Camillo, A. Perego, M. Turrini, E. Orlandi, L. Borin, A. Iurlo, S. Malato, F. Spina, M. L. Latargia, F. Lanza, S. Artale, M. Anghilieri, M. C. Carraro, G. Canal, E. MorraR. Cairoli

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined. OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.
Original languageEnglish
Pages (from-to)41-53
Number of pages13
JournalCancer Biomarkers
Volume21
Issue number1
DOIs
Publication statusPublished - Dec 12 2017

Fingerprint Dive into the research topics of 'Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment'. Together they form a unique fingerprint.

  • Cite this

    Trojani, A., Pungolino, E., Rossi, G., D'Adda, M., Lodola, M., Camillo, B. D., Perego, A., Turrini, M., Orlandi, E., Borin, L., Iurlo, A., Malato, S., Spina, F., Latargia, M. L., Lanza, F., Artale, S., Anghilieri, M., Carraro, M. C., Canal, G., ... Cairoli, R. (2017). Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. Cancer Biomarkers, 21(1), 41-53. https://doi.org/10.3233/CBM-170209 [doi]